Kameda H et al. (2005) Combination therapy with corticosteroids, cyclosporine A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol 32: 1719–1726
Patients with polymyositis or dermatomyositis are at risk of developing acute or subacute interstitial pneumonia (A/SIP), which can be fatal despite high-dose prednisolone therapy.
Kameda and colleagues undertook a pilot trial of combined immunosuppressive therapy (high-dose prednisolone, 10–30 mg/kg intravenous pulse cyclophosphamide every 3–4 weeks and 2–4 mg/kg/day cyclosporine A) for A/SIP in patients with polymyositis or dermatomyositis. In the groups included in this study, all patients who went on to develop A/SIP had dermatomyositis. Analysis of the outcomes of patients with A/SIP treated with conventional regimens prior to the trial showed that 75% died despite immunosuppressive therapy (single or sequential). Use of the pilot combined regimen in 10 patients with A/SIP doubled the survival rate to 50%: 5 patients survived and are doing well 2 years later; 5 patients died of respiratory failure within 3 months. Analysis of clinical findings in those patients who developed A/SIP showed characteristic features of mild myositis, palmar papule, fever and negative or low titer of antinuclear antibodies. Of these, the authors considered palmar papules to be a likely indication of the presence or development of A/SIP and potential fatal outcome.
The immediate use of combined immunosuppressive therapy improved outcome in patients with A/SIP and dermatomyositis, although early and aggressive treatment was still unsuccessful in around half of such patients.
Rights and permissions
About this article
Cite this article
Lovegrove, C. Improved outcome in acute or subacute interstitial pneumonia using combination therapy. Nat Rev Rheumatol 1, 70 (2005). https://doi.org/10.1038/ncprheum0031
Issue Date:
DOI: https://doi.org/10.1038/ncprheum0031